Genetically engineered mice have become the """"""""gold standard"""""""" for animal models in cancer. They are widely used to mimic human cancers with specific point mutations in tumor suppressor genes, as well as tissuespecific expression of mutations in somatic tissues. By combining several mutations in one animal, it is now possible to phenocopy human cancers that were difficult to reproduce previously in animal models. The Genetically Engineered Mouse Facility (GEMF) provides valuable resources to Cancer Center members. It generates transgenic and gene-targeted mice, performs embryo rederivations to generate pathogen-free mice, and provides cryopreservation services to archive animal models. The Mouse Resource Facility (MRF), as part of the GEMF, provides vectors for construct development, northern blots of adult and embryonic tissues, genomic DNA and cDNA libraries, and BAG filter sets. The MRF also has a small colony of Cre and lacZ transgenic mice essential for generating conditional deletions in mice. The GEMF thus provides unique opportunities to faculty to develop sophisticated animal models to study a variety of cancer problems. The GEMF has been extremely successful in generating and maintaining mouse models. In the last five years, the GEMF has generated animal models for more than 300 projects for MDACC investigators and has cryopreserved more than 120 mouse lines. A >1000% increase has been achieved in utilization of mouse resources through the MRF. The lead facility coordinator has developed new, more efficient methods of generating embryos for use by the facility. She is responsible for training faculty and their staff, and provides genetic and technical expertise to many investigators in many different programs. In addition to the facility coordinator, the GEMF is staffed by 7 highly-trained technicians. In the past five years, the GEMF has served 96 different users who represent 19 of the 20 sponsored programs;97% of the investigators served are MDACC faculty. To better serve the needs of our investigators and add needed capacity, a small satellite facility was added recently to the South Campus. This expansion will enable the GEMF to develop more models and offer additional services. The GEMF is currently funded from multiple sources, including 53% provided by the CCSG and 45% recovered through user fees, with the remainder provided by MDACC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310859
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$518,156
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Tayob, Nabihah; Richardson, Peter; White, Donna L et al. (2018) Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 18:1
Caruso, Joseph A; Duong, Mylinh T; Carey, Jason P W et al. (2018) Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78:5481-5491
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477

Showing the most recent 10 out of 12418 publications